vs

Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and M-tron Industries, Inc. (MPTI). Click either name above to swap in a different company.

ENANTA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($18.6M vs $14.2M, roughly 1.3× M-tron Industries, Inc.). M-tron Industries, Inc. runs the higher net margin — 24.1% vs -64.1%, a 88.2% gap on every dollar of revenue. On growth, M-tron Industries, Inc. posted the faster year-over-year revenue change (11.2% vs 9.8%). M-tron Industries, Inc. produced more free cash flow last quarter ($2.3M vs $-11.8M). Over the past eight quarters, M-tron Industries, Inc.'s revenue compounded faster (12.8% CAGR vs 4.5%).

Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.

M-tron Industries, Inc. designs, manufactures and markets high-performance frequency control and timing solutions including crystal oscillators, filters and integrated timing assemblies. Its products serve aerospace, defense, telecom, industrial automation and medical device segments, catering mainly to North American, European and Asian commercial and government clients.

ENTA vs MPTI — Head-to-Head

Bigger by revenue
ENTA
ENTA
1.3× larger
ENTA
$18.6M
$14.2M
MPTI
Growing faster (revenue YoY)
MPTI
MPTI
+1.4% gap
MPTI
11.2%
9.8%
ENTA
Higher net margin
MPTI
MPTI
88.2% more per $
MPTI
24.1%
-64.1%
ENTA
More free cash flow
MPTI
MPTI
$14.2M more FCF
MPTI
$2.3M
$-11.8M
ENTA
Faster 2-yr revenue CAGR
MPTI
MPTI
Annualised
MPTI
12.8%
4.5%
ENTA

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ENTA
ENTA
MPTI
MPTI
Revenue
$18.6M
$14.2M
Net Profit
$-11.9M
$3.4M
Gross Margin
Operating Margin
-60.5%
27.3%
Net Margin
-64.1%
24.1%
Revenue YoY
9.8%
11.2%
Net Profit YoY
46.4%
60.1%
EPS (diluted)
$-0.42
$0.90

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ENTA
ENTA
MPTI
MPTI
Q4 25
$18.6M
$14.2M
Q3 25
$15.1M
$14.2M
Q2 25
$18.3M
$13.3M
Q1 25
$14.9M
$12.7M
Q4 24
$17.0M
$12.8M
Q3 24
$14.6M
$13.2M
Q2 24
$18.0M
$11.8M
Q1 24
$17.1M
$11.2M
Net Profit
ENTA
ENTA
MPTI
MPTI
Q4 25
$-11.9M
$3.4M
Q3 25
$-18.7M
$1.8M
Q2 25
$-18.3M
$1.6M
Q1 25
$-22.6M
$1.6M
Q4 24
$-22.3M
$2.1M
Q3 24
$-28.8M
$2.3M
Q2 24
$-22.7M
$1.7M
Q1 24
$-31.2M
$1.5M
Operating Margin
ENTA
ENTA
MPTI
MPTI
Q4 25
-60.5%
27.3%
Q3 25
-121.6%
18.0%
Q2 25
-103.2%
13.9%
Q1 25
-164.3%
15.8%
Q4 24
-138.8%
20.1%
Q3 24
-204.4%
22.1%
Q2 24
-134.6%
17.8%
Q1 24
-192.1%
16.0%
Net Margin
ENTA
ENTA
MPTI
MPTI
Q4 25
-64.1%
24.1%
Q3 25
-123.6%
12.9%
Q2 25
-99.7%
11.7%
Q1 25
-151.7%
12.8%
Q4 24
-131.4%
16.7%
Q3 24
-197.3%
17.2%
Q2 24
-126.1%
14.8%
Q1 24
-182.7%
13.3%
EPS (diluted)
ENTA
ENTA
MPTI
MPTI
Q4 25
$-0.42
$0.90
Q3 25
$-0.88
$0.63
Q2 25
$-0.85
$0.53
Q1 25
$-1.06
$0.56
Q4 24
$-1.05
$0.68
Q3 24
$-1.36
$0.81
Q2 24
$-1.07
$0.63
Q1 24
$-1.47
$0.53

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ENTA
ENTA
MPTI
MPTI
Cash + ST InvestmentsLiquidity on hand
$37.4M
$20.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$126.6M
$63.2M
Total Assets
$329.5M
$68.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ENTA
ENTA
MPTI
MPTI
Q4 25
$37.4M
$20.9M
Q3 25
$32.3M
$18.3M
Q2 25
$44.8M
$15.5M
Q1 25
$60.2M
$13.7M
Q4 24
$84.3M
$12.6M
Q3 24
$37.2M
$8.5M
Q2 24
$35.8M
$6.5M
Q1 24
$63.5M
$5.4M
Stockholders' Equity
ENTA
ENTA
MPTI
MPTI
Q4 25
$126.6M
$63.2M
Q3 25
$64.7M
$37.0M
Q2 25
$79.3M
$34.8M
Q1 25
$93.5M
$33.2M
Q4 24
$111.8M
$31.3M
Q3 24
$128.8M
$26.2M
Q2 24
$148.9M
$23.7M
Q1 24
$166.1M
$21.7M
Total Assets
ENTA
ENTA
MPTI
MPTI
Q4 25
$329.5M
$68.4M
Q3 25
$280.7M
$42.2M
Q2 25
$301.0M
$39.7M
Q1 25
$323.0M
$37.8M
Q4 24
$348.6M
$36.6M
Q3 24
$376.7M
$31.5M
Q2 24
$398.8M
$28.4M
Q1 24
$413.6M
$26.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ENTA
ENTA
MPTI
MPTI
Operating Cash FlowLast quarter
$-11.7M
$2.7M
Free Cash FlowOCF − Capex
$-11.8M
$2.3M
FCF MarginFCF / Revenue
-63.6%
16.4%
Capex IntensityCapex / Revenue
0.8%
2.4%
Cash ConversionOCF / Net Profit
0.78×
TTM Free Cash FlowTrailing 4 quarters
$-18.5M
$8.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ENTA
ENTA
MPTI
MPTI
Q4 25
$-11.7M
$2.7M
Q3 25
$-6.5M
$3.5M
Q2 25
$17.5M
$2.9M
Q1 25
$-13.5M
$1.6M
Q4 24
$-16.8M
$1.8M
Q3 24
$-10.4M
$2.3M
Q2 24
$-14.8M
$2.0M
Q1 24
$-28.6M
$1.5M
Free Cash Flow
ENTA
ENTA
MPTI
MPTI
Q4 25
$-11.8M
$2.3M
Q3 25
$-7.9M
$2.7M
Q2 25
$17.4M
$2.0M
Q1 25
$-16.0M
$1.0M
Q4 24
$-25.5M
$1.4M
Q3 24
$-19.4M
$1.8M
Q2 24
$-21.3M
$1.1M
Q1 24
$-30.3M
$1.4M
FCF Margin
ENTA
ENTA
MPTI
MPTI
Q4 25
-63.6%
16.4%
Q3 25
-52.5%
19.1%
Q2 25
94.7%
15.4%
Q1 25
-107.4%
8.0%
Q4 24
-150.6%
10.8%
Q3 24
-132.5%
13.4%
Q2 24
-118.6%
9.2%
Q1 24
-177.5%
12.3%
Capex Intensity
ENTA
ENTA
MPTI
MPTI
Q4 25
0.8%
2.4%
Q3 25
9.6%
5.7%
Q2 25
0.8%
6.1%
Q1 25
17.0%
4.6%
Q4 24
51.6%
3.3%
Q3 24
61.3%
3.6%
Q2 24
36.4%
7.4%
Q1 24
9.8%
1.1%
Cash Conversion
ENTA
ENTA
MPTI
MPTI
Q4 25
0.78×
Q3 25
1.92×
Q2 25
1.83×
Q1 25
0.99×
Q4 24
0.85×
Q3 24
0.99×
Q2 24
1.12×
Q1 24
1.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ENTA
ENTA

Segment breakdown not available.

MPTI
MPTI

US$11.3M79%
Non Us$2.9M21%

Related Comparisons